Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
The journal of nutrition, health & aging
Published in: The journal of nutrition, health & aging 8/2016

01-10-2016

Novel therapy of hyperhomocysteinemia in mild cognitive impairment, Alzheimer’s disease, and other dementing disorders

Authors: Junko Hara, W. R. Shankle, L. W. Barrentine, M. V. Curole

Published in: The journal of nutrition, health & aging | Issue 8/2016

Login to get access

Abstract

Objectives

Studies have produced conflicting results assessing hyperhomocysteinemia (HYH) treatment with B vitamins in patients with normal cognition, Alzheimer’s disease and related disorders (ADRD). This study examined the effect of HYH management with L-methylfolate (LMF), methylcobalamin (MeCbl; B12), and N-acetyl-cysteine (CFLN: Cerefolin®/Cerefolin-NAC®) on cognitive decline.

Design

Prospective, case-control study of subjects followed longitudinally.

Setting

Outpatient clinic for cognitive disorders.

Participants

116 ADRD patients (34 with HYH, 82 with No-HYH) met inclusion and exclusion criteria to participate. No study participant took B vitamins.

Intervention

HYH patients received CFLN, and No-HYH patients did not.

Measurements

Cognitive outcome measures included MCI Screen (memory), CERAD Drawings (constructional praxis), Ishihara Number Naming (object recognition), Trails A and B (executive function), and F-A-S test (verbal fluency). Dependent or predictor measures included demographics, functional severity, CFLN and no CFLN treatment duration, ADRD diagnosis, memantine and cholinesterase inhibitor treatment. Linear mixed effects models with covariate adjustment were used to evaluate rate of change on cognitive outcomes.

Results

The duration of CFLN treatment, compared to an equivalent duration without CFLN treatment, significantly slowed decline in learning and memory, constructional praxis, and visual-spatial executive function (Trails B). CFLN treatment slowed cognitive decline significantly more for patients with milder baseline severity. CFLN treatment effect increased as baseline functional severity decreased. The analytical model showed that treatment duration must exceed some minimum period of at least one year to slow the rate of cognitive decline.

Conclusion

After covariate adjustment, HYH+CFLN significantly slowed cognitive decline compared to No-HYH+No-CFLN. Longer CFLN treatment duration, milder baseline severity, and magnitude of homocysteine reduction from baseline were all significant predictors. There are a number of factors that could account for disagreement with other clinical trials of B vitamin treatment of HYH. Moreover, CFLN is chemically distinct from commonly used B vitamins as both LMF and MeCbl are the fully reduced and bioactive functional forms; CLFN also contains the glutathione precursor, N-acetyl-cysteine. The findings of other B vitamin trials of HYH can, therefore, only partly account for treatment effects of CFLN. These findings warrant further evaluation with a randomized, placebo-controlled trial.
Literature
1.
Wong YY, Almeida OP, McCaul KA et al. Homocysteine, Frailty, and All-Cause Mortality in Older Men: The Health in Men Study. J Gerontol A Biol Sci Med Sci. 2013;68(5):590–598.CrossRefPubMed
2.
MacFarlane AJ, Greene-Finestone LS, Shi Y. Vitamin B-12 and homocysteine status in a folate-replete population: results from the Canadian Health Measures Survey. Am J Clin Nutr. 2011;94(4):1079–1087.CrossRefPubMed
3.
Selhub J, Jacques PF, Bostom AG et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev. 2000;28(1–4):117–145.PubMed
4.
Sachdev PS, Lipnicki DM, Crawford J et al. Sydney Memory and Ageing Study Team. Risk profiles for mild cognitive impairment vary by age and sex: the sydney memory and ageing study. Am J Geriatr Psychiatry. 2012;20(10):854–865.CrossRefPubMed
5.
Nie T, Lu T, Xie L, Huang P, Lu Y, Jiang M. Hyperhomocysteinemia and risk of cognitive decline: a meta-analysis of prospective cohort studies. Eur Neurol. 2014;72(3–4):241–248.PubMed
6.
Shea TB, Rogers E. Lifetime requirement of the methionine cycle for neuronal development and maintenance. Curr Opin Psychiatry. 2014;27(2):138–142.CrossRefPubMed
7.
Krupanidhi S, Sedimbi SK, Vaishnav G, Madhukar SS, Sanjeevi CB. Diabetes—role of epigenetics, genetics, and physiological factors. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009;34(9):837–845.PubMed
8.
Bruce KD, Cagampang FR. Epigenetic priming of the metabolic syndrome. Toxicol Mech Methods. 2011;21(4):353–361.CrossRefPubMed
9.
10.
Lavebratt C, Almgren M, Ekström TJ. Epigenetic regulation in obesity. Int J Obes (Lond). 2012;36(6):757–765.CrossRef
11.
Shi F, Chen X, Fu A, Hansen J, Stevens R, Tjonneland A, Vogel UB, Zheng T, Zhu Y. Aberrant DNA methylation of miR-219 promoter in long-term night shiftworkers. Environ Mol Mutagen. 2013;54(6):406–413.CrossRefPubMed
12.
Joska TM, Zaman R, Belden WJ. Regulated DNA methylation and the circadian clock: implications in cancer. Biology (Basel). 2014;3(3):560–577.PubMedPubMedCentral
13.
Liu HC, Hu CJ, Tang YC, Chang JG. A pilot study for circadian gene disturbance in dementia patients. Neurosci Lett. 2008;435(3):229–233.CrossRefPubMed
14.
Lim AS, Srivastava GP, Yu L, Chibnik LB, Xu J, Buchman AS, Schneider JA, Myers AJ, Bennett DA, De Jager PL. 24-hour rhythms of DNA methylation and their relation with rhythms of RNA expression in the human dorsolateral prefrontal cortex. PLoS Genet. 2014;10(11):e1004792.CrossRefPubMedPubMedCentral
15.
Robinson RA, Joshi G, Huang Q, Sultana R, Baker AS, Cai J, Pierce W, St Clair DK, Markesbery WR, Butterfield DA. Proteomic analysis of brain proteins in APP/ PS-1 human double mutant knock-in mice with increasing amyloid beta-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer’s disease. Proteomics. 2011;11(21):4243–4256.CrossRefPubMedPubMedCentral
16.
Szucs TD, Käser A, Riesen WF. Economic impact of hyperhomocysteinemia in Switzerland. Cardiovasc Drugs Ther. 2005;19(5):365–369.CrossRefPubMed
17.
Kwok T, Lee J, Law CB, Pan PC, Yung CY, Choi KC, Lam LC. A randomized placebo controlled trial of homocysteine lowering to reduce cognitive decline in older demented people. Clin Nutr. 2011;30(3):297–302.CrossRefPubMed
18.
Aisen PS, Schneider LS, Sano M, et al. Alzheimer Disease Cooperative Study. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300(15):1774–1783.PubMed
19.
Shankle WR, Hara J, Rafii MS, Russell J. Impact of Hyperhomocysteinemia Treatment on Cognitive Decline due to Alzheimer’s Disease and Related Disorders. JARCP. 2013;2(4): 319–324.
20.
Shankle WR, Mangrola T, Chan T, Hara J. Development and Validation of the Memory Performance Index: Reducing Measurement Error in Recall Tests. Alzheimer’s & Dementia. 2009;5:295–306.CrossRef
21.
22.
Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition. Am J Alzheimers Dis Other Demen. 2011;26(3):235–239.CrossRefPubMedPubMedCentral
23.
Reisberg B. Dementia: a systematic approach to identifying reversible causes. Geriatrics. 1986;41(4):30–46.PubMed
24.
Blasko I, Hinterberger M, Kemmler G, Jungwirth S, Krampla W, Leitha T, Heinz Tragl K, Fischer P. Conversion from mild cognitive impairment to dementia: influence of folic acid and vitamin B12 use in the VITA cohort. J Nutr Health Aging 2012;16(8):687–694.CrossRefPubMed
25.
de Jager CA, Oulhaj A, Jacoby R et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27(6):592–600.CrossRefPubMed
26.
Sassone-Corsi P. Physiology. When metabolism and epigenetics converge. Science. 2013;339(6116):148–150.PubMed
27.
Moustafa AA, Hewedi DH, Eissa AM et al. The relationship between associative learning, transfer generalization, and homocysteine levels in mild cognitive impairment. PLoS One. 2012;7(9):e46496.
28.
Sala I, Belén Sánchez-Saudinós M, Molina-Porcel L, Lázaro E, Gich I, Clarimón J, Blanco-Vaca F, Blesa R, Gómez-Isla T, Lleó A. Homocysteine and cognitive impairment. Relation with diagnosis and neuropsychological performance. Dement Geriatr Cogn Disord. 2008;26(6):506–512.CrossRefPubMed
29.
Doets EL, Ueland PM, Tell GS, Vollset SE, Nygård OK, Van’t Veer P, de Groot LC, Nurk E, Refsum H, Smith AD, Eussen SJ. Interactions between plasma concentrations of folate and markers of vitamin B(12) status with cognitive performance in elderly people not exposed to folic acid fortification: the Hordaland Health Study. Br J Nutr. 2014;111(6):1085–1095CrossRefPubMed
30.
Miller JW, Garrod MG, Allen LH, Haan MN, Green R. Metabolic evidence of vitamin B-12 deficiency, including high homocysteine and methylmalonic acid and low holotranscobalamin, is more pronounced in older adults with elevated plasma folate. Am J Clin Nutr. 2009 Dec;90(6):1586–92.CrossRefPubMedPubMedCentral
31.
Vidal JS, Dufouil C, Ducros V, Tzourio C. Homocysteine, folate and cognition in a large community-based sample of elderly people—the 3C Dijon Study. Neuroepidemiology. 2008;30(4):207–214.CrossRefPubMed
32.
Rabaneda LG, Carrasco M, Lopez-Toledano MA, Murillo-Carretero M, Ruiz FA, Estrada C, Castro C. Homocysteine inhibits proliferation of neuronal precursors in the mouse adult brain by impairing the basic fibroblast growth factor signaling cascade and reducing extracellular regulated kinase 1/2-dependent cyclin E expression. FASEB J. 2008;22(11):3823–3835.CrossRefPubMed
33.
Kruman II, Fowler AK. Impaired one carbon metabolism and DNA methylation in alcohol toxicity. J Neurochem. 2014;129(5):770–780.CrossRefPubMed
34.
Jayalakshmi K, Sairam M, Singh SB, Sharma SK, Ilavazhagan G, Banerjee PK. Neuroprotective effect of N-acetyl cysteine on hypoxia-induced oxidative stress in primary hippocampal culture. Brain Res. 2005;1046(1–2):97–104.CrossRefPubMed
35.
Unnithan AS, Choi HJ, Titler AM, Posimo JM, Leak RK. Rescue from a two hit, high-throughput model of neurodegeneration with N-acetyl cysteine. Neurochem Int. 2012;61(3):356–368.CrossRefPubMed
36.
Rideau Batista Novais A, Guiramand J, Cohen-Solal C, Crouzin N, de Jesus Ferreira MC, Vignes M, Barbanel G, Cambonie G. N-acetyl-cysteine prevents pyramidal cell disarray and reelin-immunoreactive neuron deficiency in CA3 after prenatal immune challenge in rats. Pediatr Res. 2013;73(6):750–755.CrossRefPubMed
37.
Otte DM, Sommersberg B, Kudin A, Guerrero C, Albayram O, Filiou MD, Frisch P, Yilmaz O, Drews E, Turck CW, Bilkei-Gorzó A, Kunz WS, Beck H, Zimmer A. N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology. 2011;36(11):2233–2243.CrossRefPubMedPubMedCentral
38.
Cheng Y, Jin Y, Unverzagt FW, Su L, Yang L, Ma F, Hake AM, Kettler C, Chen C, Liu J, Bian J, Li P, Murrell JR, Hendrie HC, Gao S. The relationship between cholesterol and cognitive function is homocysteine-dependent. Clin Interv Aging. 2014;9:1823–1829.PubMedPubMedCentral
39.
Glushchenko AV, Jacobsen DW. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. Antioxid Redox Signal. 2007;9(11):1883–1898.CrossRefPubMedPubMedCentral
40.
Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T, Mäkelä M, Oinas M, Paetau A, Scheltens P, van Straaten EC, Sulkava R, Solomon A. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a populationbased autopsy study. Brain. 2013;136(Pt 9):2707–2716.CrossRefPubMedPubMedCentral
41.
Fuso A, Nicolia V, Cavallaro RA, Ricceri L, D’Anselmi F, Coluccia P, Calamandrei G, Scarpa S. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice.31. Mol Cell Neurosci. 2008;37(4):731–746.CrossRefPubMed
42.
Schaub C, Uebachs M, Beck H, Linnebank M. Chronic homocysteine exposure causes changes in the intrinsic electrophysiological properties of cultured hippocampal neurons. Exp Brain Res. 2013;225(4):527–534.CrossRefPubMed
43.
Görtz P, Hoinkes A, Fleischer W, Otto F, Schwahn B, Wendel U, Siebler M. Implications for hyperhomocysteinemia: not homocysteine but its oxidized forms strongly inhibit neuronal network activity. J Neurol Sci. 2004 Mar 15;218(1–2):109–14.CrossRefPubMed
Metadata
Title
Novel therapy of hyperhomocysteinemia in mild cognitive impairment, Alzheimer’s disease, and other dementing disorders
Authors
Junko Hara
W. R. Shankle
L. W. Barrentine
M. V. Curole
Publication date
01-10-2016
Publisher
Springer Paris
Published in
The journal of nutrition, health & aging / Issue 8/2016
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI
https://doi.org/10.1007/s12603-016-0688-z

Other articles of this Issue 8/2016

The journal of nutrition, health & aging 8/2016 Go to the issue

OriginalPaper

Prevalence of and risk factors for dysphagia in the community dwelling elderly: A systematic review

OriginalPaper

Metabolic syndrome is not an independent risk factor for hearing impairment

OriginalPaper

Mini Nutritional Assessment short-form: Validation in five Latin American cities. SABE study

OriginalPaper

Early nutritional follow-up after discharge prevents deterioration of ADL functions in malnourished, independent, geriatric patients who live alone–A randomized clinical trial

OriginalPaper

Vitamin C supplementation, APOE4 genotype and cognitive functioning in a rural-dwelling cohort

OriginalPaper

Is meeting the recommended dietary allowance (RDA) for protein related to body composition among older adults?: Results from the Cardiovascular Health of Seniors and Built Environment Study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits